Nanoparticles News and Research

RSS

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

Dr Martin Muschol, Assistant Professor at the University of South Florida’s (USF) Department of Physics and his team are carrying out important research to gain a better understanding of protein aggregation phenomena, including protein crystallization and amyloid fibril growth. Using the Zetasizer Nano ZS, from Malvern Panalytical (Malvern Panalytical, UK), the USF researchers have been able to perform temperature controlled static and dynamic light scattering (DLS) measurements of protein hydration, protein interactions and aggregation kinetics in vitro.

From Malvern Panalytical 15 Apr 2010

Lauric-acid-filled nano-scale bombs for treating acne

A natural product found in both coconut oil and human breast milk - lauric acid -- shines as a possible new acne treatment thanks to a bioengineering graduate student from the UC San Diego Jacobs School of Engineering. The student developed a "smart delivery system" - published in the journal ACS Nano in March - capable of delivering lauric-acid-filled nano-scale bombs directly to skin-dwelling bacteria (Propionibacterium acnes) that cause common acne.

15 Apr 2010

New medical imaging technique using pulsed laser and nanocages

New research findings suggest that an experimental ultrasensitive medical imaging technique that uses a pulsed laser and tiny metallic "nanocages" might enable both the early detection and treatment of disease.

13 Apr 2010

Researchers report major step forward in effort to understand and engineer protein structure

Researchers in Singapore are reporting this week that they have gleaned key insights into the architecture of a protein that controls iron levels in almost all organisms. Their study culminated in one of the first successful attempts to take apart a complex biological nanostructure and isolate the rules that govern its natural formation.

12 Apr 2010

Researchers investigate effects of nanoparticles on yeast

Nanoparticles are already widely used in everyday products such as cosmetics, textiles, dyes, and paints. It is quite possible that these minute fragments of matter may in future not only come to play a crucial role in medicine and pharmacology, but also in the food and biotechnology industries. The latest research currently being conducted in India has shown that nanoparticles can promote the growth of fungi and even assist plant growth.

12 Apr 2010

Study suggests new ways to improve anti-cancer chemotherapies

A study released this week suggests that anti-cancer chemotherapies which use nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells, according to a team of chemists and chemical engineers at the University of Massachusetts Amherst.

12 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Potential toxicity of zinc nanoparticles in sunscreen products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death. Their study is in ACS' Chemical Research in Toxicology, a monthly journal.

8 Apr 2010

FDA-approved contrast agent improves optical imaging of stem cells

A study published in the current issue of Cell Transplantation (19:1) has found that using the FDA-approved contrast agent Indocyanine Green (ICG) to label human embryonic stem cell-derived cardiomyocytes (hESC-CMs) substantially improved efforts to optically track stem cells after transplanting them into heart tissues.

6 Apr 2010

Selecta Biosciences raises $15M in new Series C financing round

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.

5 Apr 2010

Gold nanoparticles for detecting melamine in milk

University of Miami assistant professor in the College of Engineering, Na Li and her collaborators have developed a fast, economical and easy method to detect melamine in milk. Melamine is the compound found in contaminated pet food and in tainted dairy products from China in 2007 and 2008 respectively.

2 Apr 2010

Ensuring medication compliance in clinical trials: Pill capsules with microchips to signal ingestion

Seeking a way to confirm that patients have taken their medication, University of Florida engineering researchers have added a tiny microchip and digestible antenna to a standard pill capsule. The prototype is intended to pave the way for mass-produced pills that, when ingested, automatically alert doctors, loved ones or scientists working with patients in clinical drug trials.

1 Apr 2010

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Take a look at this: Scientists from Buffalo, Cleveland, and Oklahoma City made a huge step toward making the blind see, and they did it by using a form of gene therapy that does not involve the use of modified viruses.

1 Apr 2010

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

1 Apr 2010

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

Preliminary research on cancer treatments using nanotechnology and laser therapy has led to a National Science Foundation (NSF) Faculty Early Career Development (CAREER) award for Marissa Nichole Rylander, Virginia Tech assistant professor jointly appointed in the Department of Mechanical Engineering and Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences (SBES).

30 Mar 2010

Biophotonics: Light to cure disease

Biophotonics, or photomedicine, is a relatively unknown discipline, though it has existed for years now. You may have even benefited from it without realizing it. Some of the greatest advances of this field can be found in applications for the areas of oncology, dermatology, ophthalmology, surgery and cardiology.

27 Mar 2010

VisEn Medical announces launch of new GastroSense 750 fluorescence agent for imaging gastric motility

VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new GastroSense™ 750 fluorescence agent for imaging gastric motility and related drug effects in vivo.

26 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010